Cover Image

Bioanalytical method development and validation of linagliptin in plasma through LC-MS/MS

Mahamad Shafi S.S.*, Arifa Begum, Saradhi N. D.V.R.

Abstract


The objective of the study was to develop and validate simple, selective, specific Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS) method for the determination of Linagliptin in Human Plasma. The accuracy and precision data must fulfill the requirements for the quantification of analytes in biological matrices to produce data for bioavailability, bioequivalence, etc. The separation of the analyte was carried out on    Waters, X-Bridge, C18, 5μm column having 4.6×50 mm internal diameter and the mobile phase containing acetonitrile and 0.1 % formic acid (90:10 v/v) at a flow rate of 0.6 mL/min. The retention times of  Linagliptin and Telmisartan (Internal Standard ) were  1.45 min and  1.20 min  simultaneously and the total run time was 3.0 min. Monitoring of  the fragmentation of  m / z  473.54 → 157.6 performed during MS/MS detection of  Linagliptin and Internal Standard (I.S.) on the mass spectrometer. The overall recovery of Linagliptin and IS was 92.5 % and 89.9 % respectively. The matrix effect of Linagliptin and IS was 5.51 and 1.33 % respectively. The method was validated over the concentration range of 10ng/mL to 5000ng/mL. Multiple Reaction Monitoring (MRM) mode was used as an operating mode in the mass spectrometer.  Ion spray was kept in positive mode for the detection of Analyte and IS during the production of ions. The method was validated for linearity, accuracy, precision, specificity, selectivity, inter and intraday precision, LQC, HQC.

Keywords


Linagliptin; Bioavailability; Validation; Accuracy; LC-MS/MS.

Full Text:

PDF

References


Yki-Jarvinen H, Thizolidinediones N. Engl J Med, 2004, 351, 1106-1118.

Elrick H, Stimmler L, Hald CJ, Rai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab, 1964, 24, 1076-1082.

Deacon CF. What do we know about secretion and degradation of incretin hormones? Regul Pept 2005, 128, 117-124.

Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment .Pharmacol Rev, 2008, 60, 470-512.

Laxman Raju Badugu. Am. J. pharm Tech Res., 2012, 2, 462-470.

Archana M, N. Sriram, Md. Gayasuddin. IJMCA, 2013, 3, 1-5.

FDA Approved Type 2 Diabetes drug from Boehringer Ingelhiem and Lilly. 2011, 3 May.

Stefan Belch, Eva Ludwig-Shwellinger, Eva Ulrike graphe-Mody, Barbara Withopf and Klaus Wagner. 2010, 38, 667-678.

Lakshmi B, TV Reddy, Jamonline, 2012, 2, 155-164.

Kavitha KY, Geetha G, Hariprasad R, Kaviarasu M, Venkatanarayana R. J. Chem. Pharm. Res., 2013, 5, 230-235.

Jin Hee Yu, Hye Jin Kim, Sibeum Lee, Sung -Joo Hwang, Won Kim, Cheol Jin Moon. JPAB, 2004, 36, 421-427.

ZAE Sherif, AO Mohamed, MI Walash F, M Trras. J. Pharm. Biomed. Anal. 2000, 22, 13-23.

H He, A Sadeque, JCL Erve, AJJ Wood, DL Hache, J. Chromatogr. B, 2000, 744, 323-331.

Das Binaya, Asian. J. Pharm. Clin. Res. 2013, 6 , 213-216.




DOI: http://dx.doi.org/10.21746/ijbio.2014.07.007

Refbacks

  • There are currently no refbacks.




Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.